High-dose cyclophosphamide treatment for refractory severe aplastic anemia in children

Pediatric Blood and Cancer

Volumn 54, Issue 2, 2010, Pages 269-272

  Audino, Anthony N ^a   Blatt, Julie ^b   Carcamo, Benjamin ^c   Castaneda, Victoria ^d   Dinndorf, Patricia ^e,f   Wang, Winfred C ^g   Whitlock, James A ^h   Hord, Jeffrey D ^a  

^a AKRON CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Providence Memorial Hospital   (United States)

^d East Tennessee Children's Hospital   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h VANDERBILT UNIVERSITY   (United States)

Author keywords

Aplastic anemia; Children; Cyclophosphamide; Refractory

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; FLUCONAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MESNA; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; ASPERGILLUS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FEVER; GINGIVITIS; HEMATOCRIT; HEMORRHAGIC CYSTITIS; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REFRACTORY ANEMIA; SCHOOL CHILD; SEPSIS; SERUM SICKNESS; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ANEMIA, APLASTIC; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; SALVAGE THERAPY;

EID: 74849111526     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22312     Document Type: Article

References (25)

1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108:2509-2519.
2. Scheinberg P, Wu C, Nunez O. et al. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr 2008. 153: 814-819.
3. Camitta BM, Storb R, Thomas ED. Aplastic anemia (second of two parts): Pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med 1982;306:712-718.
4. Li FP, Alter BP, Nathan DG. The mortality of acquired aplastic anemia in children. Blood 1972;40:153-162.
5. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000;37: 30-42.
6. Kurre P, Johnson FL, Deeg HJ. Diagnosis and treatment of children with aplastic anemia. Pediatr Blood Cancer 2005;45:770-780.
7. Camitta BM, Doney K. Immunosuppressive therapy for aplastic anemia: Indications, agents, mechanisms, and results.Am J Pediatr Hematol Oncol 1990;12:411-424.
8. Pongtanakul B, Das PK, Charpentierk, et al. Outcome of children with aplastic anemia treated with immunosuppressive therapy. Pediatr Blood Cancer 2008;50:52-57.
9. Rosenfeld S, Follmann D, Nunez O. et al. Antithymocyte globulin and cyclosporine for severe aplastic anemia: Association between hematologic response and long-term outcome. J Am Med Assoc 2003;289:1130-1135.
10. Di Bona E, Rodeghiero F, Bruno B. et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1999;107:330-334.
11. Tichelli A, Passeg J, Nissen C. et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol 1998;100:393-400.
12. Deeg HJ,O'Donnell M, Tolar L. et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006;108:1485-1491.
13. Yoshimi A, Kojima S, Taniguehi S. et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant 2008;14:1057-1063.
14. Maury S, Belere-Appert M, Chir Z. et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: Improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 2007;92:589-596.
15. Kojima S, Matsuyama T, Kato S. et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: The Japan Marrow Donor Program. Blood 2002;100:799-803.
16. Brodsky RA, Chen AR, Brodsky I. et al. High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. Exp Hematol 2004;32:435-440.
17. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood 1996;87:491-494.
18. Brodsky RA, Sensenbrenner L, Smith B. et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 2001; 135:477-483.
19. Jaime-Perez JC, Gonzalez-Llano O, Gomez-Almaguer D. High-dose cyclophosphamide in the treatment of severe aplastic anemia in children. Am J Hematol 2001;66:71.
20. Tisdale JF, Dunn DE, Geller N. et al. High-dose cyclophosphamide in severe aplastic anaemia: A randomised trial. Lancet 2000;356: 1554-1559.
21. Marsh JC. Treatment of aplastic anaemia: First do no harm. Lancet 2000;356:1536-1537.
22. Cairo MS, Sposto R, Hoover-Regan M. et al. Childhood and adolescent large-cell lymphoma (LCL): A review of the Children's Cancer Group experience. Am J Hematol 2003;72:53-63.
23. Zage PE, Kletzel M, Murray K. et al. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:747-753.
24. Goldenberg NA, Graham D, Liang X. et al. Successful treatment of severe aplastic anemia in children using standardized immunosuppressive therapy with antithymocyte globulin and cyclosporine A. Pediatr Blood Cancer 2004;43:718-722.
25. Karanes C, Nelson G, Chitphakdithai P. et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008;14:8-15.